15 results on '"Pintó X"'
Search Results
2. Consenso sobre Lipoproteina(a) de la Sociedad Española de Arteriosclerosis. Revisión bibliográfica y recomendaciones para la práctica clínica
- Author
-
Delgado-Lista, J, Mostaza, JM, Arrobas-Velilla, T, Blanco-Vaca, F, Masana, L, Pedro-Botet, J, Perez-Martinez, P, Civeira, F, Cuende-Melero, JI, Gomez-Barrado, JJ, Lahoz, C, Pintó, X, Suarez-Tembra, M, Lopez-Miranda, J, and Guijarro, C
- Abstract
La irrupción de la lipoproteína (a) (Lp(a)) en el estudio de los factores de riesgo cardiovascular es quizás, junto con el descubrimiento y uso de los fármacos inhibidores de la proproteína convertasa subtilisina/kexina tipo 9, (iPCSK9), la mayor novedad en el campo desde hace décadas. La concentración de Lp(a) (especialmente los niveles muy elevados) tiene una innegable asociación con determinadas complicaciones cardiovasculares, como los derivados de enfermedad vascular aterosclerótica (EVA) y o la estenosis aórtica. Sin embargo, existen varias limitaciones actuales tanto para establecer asociaciones epidemiológicas como para realizar un tratamiento farmacológico específico. En primer lugar, la medición de la Lp(a) depende en gran medida del test utilizado, principalmente por las características de la molécula. En segundo lugar, la concentración de Lp(a) está determinada en más del 80% por la genética, por lo que, al contrario de otros factores de riesgo cardiovascular no puede ser regulada con cambios del estilo de vida. Finalmente, aunque existen múltiples ensayos clínicos prometedores con fármacos específicos para reducir la Lp(a), actualmente solo los iPCSK9 (limitados para su uso por su coste) reducen de forma significativa la Lp(a).
- Published
- 2024
- Full Text
- View/download PDF
3. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention.
- Author
-
Marco-Benedí V, Sánchez-Hernández RM, Díaz JL, Jarauta E, Suárez-Tembra M, Pintó X, Morillas C, Plana N, Pedro-Botet J, and Civeira F
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Hypercholesterolemia drug therapy, Hypercholesterolemia blood, Primary Prevention methods, Anticholesteremic Agents therapeutic use, Registries, Proprotein Convertase 9 metabolism, Antibodies, Monoclonal, Humanized therapeutic use, PCSK9 Inhibitors therapeutic use, Secondary Prevention methods, Cardiovascular Diseases prevention & control, Cardiovascular Diseases drug therapy, Cholesterol, LDL blood
- Abstract
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiovascular disease (CVD) or those at very high risk do not reach their therapeutic LDLc objectives., Objective: The analysis aimed to examine the clinical and biochemical characteristics of subjects receiving PCSK9i treatment in the Dyslipidemia Registry of the Spanish Atherosclerosis Society., Methods: All consecutive subjects aged ≥ 18 years from different Lipid Units included in the Dyslipidemia Registry of the SEA were analyzed. Inclusion criteria consisted of unrelated patients aged ≥ 18 at the time of inclusion with hypercholesterolemia (LDL-C ≥ 130 mg/dL or non-HDL-C ≥ 160 mg/dL after the exclusion of secondary causes) who were studied for at least two years after inclusion. Participants' baseline and final visit clinical and biochemical characteristics were analyzed based on whether they were on primary or secondary prevention and whether they were taking PCSK9i at the end of follow-up., Results: Eight hundred twenty-nine patients were analyzed, 7014 patients in primary prevention and 1281 in secondary prevention at baseline. 4127 subjects completed the required follow-up for the final analysis. The median follow-up duration was 7 years (IQR 3.0-10.0). Five hundred patients (12.1%) were taking PCSK9i at the end of the follow-up. The percentage of PCSK9i use reached 35.6% (n = 201) and 8.7% (n = 318) in subjects with and without CVD, respectively. Subjects on PCSK9i and oral lipid-lowering agents with and without CVD achieved LDLc reductions of 80.3% and 75.1%, respectively, concerning concentrations without lipid-lowering drugs. Factors associated with PCSK9i use included increasing age, LDLc without lipid-lowering drugs and the Dutch Lipid Clinic Network (DLCN) score. However, hypertension, diabetes, smoking, and LDLc after oral lipid-lowering drugs were not independent factors associated with PCSK9i prescription. In subjects with CVD, the use of PCSK9i was higher in men than in women (an odds ratio of 1.613, P = 0.048)., Conclusions: Approximately one-third of CVD patients received PCSK9i at the end of follow-up. The use of PCSK9i was more focused on baseline LDLc concentrations rather than on CVD risk. Women received less PCSK9i in secondary prevention compared to men., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Long-term association between water intake and kidney function in a population at high cardiovascular risk.
- Author
-
Paz-Graniel I, Valle-Hita C, Babio N, Serra-Majem L, Vioque J, Zomeño MD, Corella D, Pintó X, Cano-Ibáñez N, Tur JA, Cuadrado-Soto E, Martínez JA, Díaz-López A, Torres-Collado L, Goday A, Fernández-Carrión R, Nissenshon M, Riera-Mestre A, Garrido-Garrido E, Bouzas C, Abete I, Daimiel L, Cornejo-Pareja I, Vázquez-Ruiz Z, Khoury N, Pérez-Vega KA, and Salas-Salvadó J
- Abstract
Objectives: The evidence on water intake in the prevention of kidney function decline is scarce at population level in well-being individuals at high cardiovascular risk. Therefore, we aimed to longitudinally evaluate the associations between total water intake and subtypes and kidney function, through estimated-Glomerular Filtration Rate (eGFR)., Methods: Three-year prospective analysis conducted in 1986 older adults (aged 55-75 year) with overweight/obesity and metabolic syndrome from the PREDIMED-Plus study. Water intake was assessed using validated beverage and food frequency questionnaires. Serum creatinine-based eGFR (SCr-based eGFR; ml/min/1.73 m
2 ) was estimated using the CKD-EPI equation at baseline, one-year and 3-years of follow-up. Mixed-effects linear regression models were fitted to evaluate the associations between baseline total water intake and subtypes, and SCr-based eGFR over 3-years of follow-up., Results: Participants in the highest baseline tertile of total water intake, plain water and water from all fluids showed a lower decrease in SCr-based eGFR after 3-years of follow-up, compared to those in the lowest tertile. Participants with the highest tap water consumption showed a lower SCr-based eGFR decline after 1-year and 3-years of follow-up, in comparerd to participants in the lowest intake category (T3 vs. T1: β: 1.4 ml/min/1.73 m2 ; 95%CI: 0.5-2.3, β: 1.0; 95%CI: 0.1-2.0, respectively)., Conclusions: Plain water rather than other water sources, and especially tap water, was associated with lower kidney function decline assessed through eGFR over 3-years of follow-up, in older individuals at high cardiovascular risk., Trial Registration: ISRCTN89898870. Retrospectively registered on 24 July 2014., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
5. Objectively Measured Sleep Duration and Health-Related Quality of Life in Older Adults with Metabolic Syndrome: A One-Year Longitudinal Analysis of the PREDIMED-Plus Cohort.
- Author
-
Marcos-Delgado A, Martín-Sánchez V, Martínez-González MÁ, Corella D, Salas-Salvadó J, Schröder H, Martínez A, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Santos-Lozano JM, Álvarez-Pérez J, Bueno-Cavanillas A, Cano-Ibáñez N, Amezcua-Prieto C, Hernández-Segura N, Tur JA, Pintó X, Delgado-Rodríguez M, Matía-Martín P, Vidal J, Vázquez C, Daimiel L, Ros E, Toledo E, Garcidueñas-Fimbres TE, Viaplana J, Asensio EM, Zomeño MD, Garcia-Rios A, Oncina-Cánovas A, Barón-López FJ, Pérez-Farinos N, Sayon-Orea C, Galmés-Panadés AM, Casas R, Tojal-Sierra L, Gómez-Pérez AM, Buil-Corsiales P, García-Gavilán JF, Ortega-Azorín C, Castañer O, Peña-Orihuela PJ, González-Palacios S, Babio N, Fitó M, and Nieto J
- Subjects
- Humans, Aged, Middle Aged, Male, Female, Longitudinal Studies, Cross-Sectional Studies, Spain epidemiology, Time Factors, Surveys and Questionnaires, Accelerometry, Healthy Lifestyle, Sleep Duration, Quality of Life, Sleep physiology, Metabolic Syndrome psychology, Metabolic Syndrome epidemiology
- Abstract
The aim of our cross-sectional and longitudinal study is to assess the relationship between daytime and night-time sleep duration and health-related quality of life (HRQoL) in adults with metabolic syndrome after a 1-year healthy lifestyle intervention. Analysis of the data from 2119 Spanish adults aged 55-75 years from the PREDIMED-Plus study was performed. Sleep duration was assessed using a wrist-worn accelerometer. HRQoL was measured using the SF-36 questionnaire. Linear regression models adjusted for socioeconomic and lifestyle factors and morbidity were developed. In cross-sectional analyses, participants with extreme night-time sleep duration categories showed lower physical component summary scores in Models 1 and 2 [β-coefficient (95% confidence interval) <6 h vs. 7-9 h: -2, 3 (-3.8 to -0.8); p = 0.002. >9 h vs. 7-9 h: -1.1 (-2.0 to -0.3); p = 0.01]. Participants who sleep less than 7 h a night and take a nap are associated with higher mental component summary scores [β-coefficient (95% confidence interval) 6.3 (1.3 to 11.3); p = 0.01]. No differences between night-time sleep categories and 12-month changes in HRQoL were observed. In conclusion, in cross-sectional analyses, extremes in nocturnal sleep duration are related to lower physical component summary scores and napping is associated with higher mental component summary scores in older adults who sleep less than 7 h a night.
- Published
- 2024
- Full Text
- View/download PDF
6. COVID-19 and Cognitive Decline in Older Adults with High-Cardiovascular Risk: A Post Hoc Analysis.
- Author
-
Shyam S, Gómez-Martínez C, Ni J, Gaforio JJ, Martínez-González MÁ, Corella D, Martínez JA, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem L, Bueno-Cavanillas A, Tur JA, Martín-Sánchez V, Pintó X, Delgado-Rodríguez M, Matía-Martín P, Vidal J, Vázquez C, Daimiel L, Ros E, Fernandez-Aranda F, Hernández-Cacho A, Buil-Cosiales P, Sorli JV, Castañer O, Garcia-Rios A, Oncina-Canovas A, Pérez-Farinós N, Nafria M, Casas R, Martínez-Diz S, Tojal-Sierra L, Am GP, Toledo E, Fernández-Carrión R, Bayón ÁM, Torres-Peña JD, Compañ-Gabucio L, Vázquez-Ruiz Z, Babio N, Fitó M, and Salas-Salvadó J
- Abstract
Cognitive decline has been reported as a short-term sequela in patients hospitalized for coronavirus disease-19 (COVID-19). Whether COVID-19 is associated with late cognitive impairment in older free-living individuals with high cardiovascular risk, a group at greater risk of cognitive decline, is unknown. We determined this association of COVID-19 through a longitudinal evaluation of post-COVID-19 cognitive performance and impairment as post hoc analysis in 5,179 older adults (48% female) with mean (SD) age 68.5 (5.0) years, body mass index 31.7 (3.7) kg/m
2 , harboring ≥ 3 criteria for metabolic syndrome (e.g., hypertension, hyperlipidemia, hyperglycemia etc.) enrolled in PREDIMED-Plus trial. Pre- and post-COVID-19 cognitive performance was ascertained from scheduled assessments conducted using a battery of neuropsychological tests, including 5 domains: Global Cognitive Function, General Cognitive Function, Execution Function, Verbal Fluency and Attention domains, which were standardized for the cohort. Cognitive impairment was defined as the bottom 10 percentile of the sample. Multivariable linear and logistic regression models assessed the association of COVID-19 with cognitive decline and impairment, respectively. After a mean 50-week follow-up, no significant associations were observed between COVID-19 status and post-COVID-19 scores of all tapped neuropsychological domains, except Global Cognitive Function (GCF). When fully adjusted, COVID-19 was marginally associated with higher (better) post-pandemic GCF score (βadj (95% CI): 0.06 (0.00, 0.13) p=.05). However, the odds for post-COVID-19 cognitive impairment in GCF domain were not associated with the disease (ORadj (95% CI): 0.90 (0.53, 1.51) p=.68). In the PREDIMED-Plus cohort, COVID-19 status and cognitive impairment determined 50 weeks post-infection showed no association in older adults at high cardiovascular risk. This suggests that cognitive changes observed shortly after COVID-19 revert over time. However, cautious interpretation is warranted as these data were obtained within the framework of a clinical trial encouraging a healthy lifestyle.- Published
- 2024
- Full Text
- View/download PDF
7. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice.
- Author
-
Delgado-Lista J, Mostaza JM, Arrobas-Velilla T, Blanco-Vaca F, Masana L, Pedro-Botet J, Perez-Martinez P, Civeira F, Cuende-Melero JI, Gomez-Barrado JJ, Lahoz C, Pintó X, Suarez-Tembra M, Lopez-Miranda J, and Guijarro C
- Subjects
- Humans, PCSK9 Inhibitors, Spain, Atherosclerosis, Consensus, Arteriosclerosis, Lipoprotein(a) blood, Cardiovascular Diseases prevention & control, Cardiovascular Diseases etiology, Heart Disease Risk Factors
- Abstract
The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a). However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a)., (Copyright © 2024 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Effect of a nutritional intervention based on an energy-reduced Mediterranean diet on environmental impact.
- Author
-
Álvarez-Álvarez L, Rubín-García M, Vitelli-Storelli F, García S, Bouzas C, Martínez-González MÁ, Corella D, Salas-Salvadó J, Malcampo M, Martínez JA, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-Majem L, Bueno-Cavanillas A, García Fernández C, Pintó X, Delgado-Rodríguez M, Matía-Martín P, Vidal J, Vázquez C, Daimiel L, Ros E, García-Arellano A, Martínez MÁ, Sorlí JV, Zomeño MD, García-Rios A, González-Palacios S, Monserrat-Mesquida M, Abete I, Colom Fernández A, Casas R, Cano Ibáñez N, Ugarriza L, Bernal-López MR, Bes-Rastrollo M, Paz-Graniel I, Asensio EM, Fitó M, Arenas Larriva AP, Oncina-Cánovas A, Vázquez Z, Fernández de la Puente M, Pérez-Vega A, Tur JA, and Martín-Sánchez V
- Subjects
- Middle Aged, Humans, Aged, Male, Female, Environment, Greenhouse Gases analysis, Eutrophication, Metabolic Syndrome prevention & control, Diet, Mediterranean
- Abstract
Objective: To estimate the environmental impact of a dietary intervention based on an energy-reduced Mediterranean diet (MedDiet) after one year of follow-up., Methods: Baseline and 1-year follow-up data were used for 5800 participants aged 55-75 years with metabolic syndrome in the PREDIMED-Plus study. Food intake was estimated through a validated semiquantitative food consumption frequency questionnaire, and adherence to the MedDiet was estimated through the Diet Score. Using the EAT-Lancet Commission tables we assessed the influence of dietary intake on environmental impact (through five indicators: greenhouse gas emissions (GHG), land use, energy used, acidification and potential eutrophication). Using multivariable linear regression models, the association between the intervention and changes in each of the environmental factors was assessed. Mediation analyses were carried out to estimate to what extent changes in each of 2 components of the intervention, namely adherence to the MedDiet and caloric reduction, were responsible for the observed reductions in environmental impact., Results: We observed a significant reduction in the intervention group compared to the control group in acidification levels (-13.3 vs. -9.9 g SO2-eq), eutrophication (-5.4 vs. -4.0 g PO4-eq) and land use (-2.7 vs. -1.8 m2). Adherence to the MedDiet partially mediated the association between intervention and reduction of acidification by 15 %, eutrophication by 10 % and land use by 10 %. Caloric reduction partially mediated the association with the same factors by 55 %, 51 % and 38 % respectively. In addition, adherence to the MedDiet fully mediated the association between intervention and reduction in GHG emissions by 56 % and energy use by 53 %., Conclusions: A nutritional intervention based on consumption of an energy-reduced MedDiet for one year was associated with an improvement in different environmental quality parameters., Competing Interests: Declaration of competing interest J.S.-S. reported receiving research support from the Instituto de Salud Carlos III, Ministerio de Educación y Ciencia, the European Commission, the USA National Institutes of Health; receiving consulting fees or travel expenses from Eroski Foundation and Instituto Danone, receiving nonfinancial support from Hojiblanca, Patrimonio Comunal Olivarero, the California Almond Board of California, Pistachio Growers and Borges S.A; serving on the board of and receiving grant support through his institution from the International Nut and Dried Foundation and the Eroski Foundation; and personal fees from Instituto Danone Spain; Serving in the Board of Danone Institute International. D·C. reported receiving grants from Instituto de Salud Carlos III. R.E. reported receiving grants from Instituto de Salud Carlos III, Fundación Dieta Meditarránea and Cerveza y Salud and olive oil for the trial from Fundación Patrimonio Comunal Olivarero and personal fees from Brewers of Europe, Fundación Cerveza y Salud, Interprofesional del Aceite de Oliva, Instituto Cervantes in Albuquerque, Milano and Tokyo, Pernod Ricard, Fundación Dieta Mediterránea (Spain), Wine and Culinary International Forum and Lilly Laboratories; nonfinancial support from Sociedad Española de Nutrición and Fundación Bosch y Gimpera; and grants from Uriach Laboratories. The rest of the authors have declared that no competing interests exist. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. SEA 2024 Standards for Global Control of Vascular Risk.
- Author
-
Mostaza JM, Pintó X, Armario P, Masana L, Real JT, Valdivielso P, Arrobas-Velilla T, Baeza-Trinidad R, Calmarza P, Cebollada J, Civera-Andrés M, Cuende Melero JI, Díaz-Díaz JL, Espíldora-Hernández J, Fernández Pardo J, Guijarro C, Jericó C, Laclaustra M, Lahoz C, López-Miranda J, Martínez-Hervás S, Muñiz-Grijalvo O, Páramo JA, Pascual V, Pedro-Botet J, Pérez-Martínez P, and Puzo J
- Subjects
- Humans, Spain, Global Health, Risk Factors, Heart Disease Risk Factors, Cardiovascular Diseases prevention & control, Cardiovascular Diseases etiology, Societies, Medical standards, Vascular Diseases prevention & control, Vascular Diseases diagnosis, Atherosclerosis prevention & control, Atherosclerosis diagnosis
- Abstract
One of the objectives of the Spanish Society of Arteriosclerosis is to contribute to the knowledge, prevention and treatment of vascular diseases, which are the leading cause of death in Spain and entail a high degree of disability and health expenditure. Atherosclerosis is a multifactorial disease and its prevention requires a global approach that takes into account the associated risk factors. This document summarises the current evidence and includes recommendations for patients with established vascular disease or at high vascular risk: it reviews the symptoms and signs to evaluate, the laboratory and imaging procedures to request routinely or in special situations, and includes the estimation of vascular risk, diagnostic criteria for entities that are vascular risk factors, and general and specific recommendations for their treatment. Finally, it presents aspects that are not usually referenced in the literature, such as the organisation of a vascular risk consultation., (Copyright © 2024 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
10. Resilient Older Subjects with Heterozygous Familial Hypercholesterolemia, Baseline Differences and Associated Factors.
- Author
-
Climent E, González-Guerrero A, Marco-Benedí V, García-Andreu MD, Mediavilla-García JD, Suárez-Tembra M, Benaiges D, Pintó X, and Pedro-Botet J
- Subjects
- Humans, Female, Male, Aged, Risk Factors, Cholesterol, LDL blood, Atherosclerosis blood, Atherosclerosis etiology, Atherosclerosis genetics, Cholesterol, HDL blood, Lipoprotein(a) blood, Aged, 80 and over, Hyperlipoproteinemia Type II blood, Hyperlipoproteinemia Type II genetics, Heterozygote
- Abstract
Despite elevated low-density lipoprotein (LDL) cholesterol levels, some older subjects with heterozygous familial hypercholesterolemia (HeFH) do not develop atherosclerotic cardiovascular disease (ACVD) during their lifetime. The factors related to this resilient state have not been fully established. The aim of this study was to evaluate differential characteristics between older HeFH subjects with and without ACVD and factors associated with the presence of ACVD. Subjects were part of the Spanish Atherosclerosis Society Dyslipidemia Registry, and those ≥ 70 years old and with HeFH were included. Baseline characteristics of these subjects with and without ACVD were compared. A multivariate analysis was performed to assess factors associated with the presence of ACVD. A total of 2148 subjects with HeFH were included. Resilient subjects were mostly female, younger and presented fewer comorbidities with respect to the ACVD group. Subjects without ACVD had higher baseline high-density lipoprotein (HDL) cholesterol (55.8 ± 17.1 vs. 47.9 ± 15.4 mg/dL; p < 0.001) and lower lipoprotein(a) [Lp(a)] (53.4 ± 67.9 vs. 66.6 ± 85.6 mg/dL; p < 0.001) levels with respect to those in the ACVD group. Lp(a) and the presence of ≥3 risk factors were associated with the presence of ACVD.
- Published
- 2024
- Full Text
- View/download PDF
11. Dietary intake of Perfluorooctanesulfonic acid (PFOS) and glucose homeostasis parameters in a non-diabetic senior population.
- Author
-
Khoury N, Ángeles Martínez M, Nishi SK, Ángel Martínez-González M, Corella D, Castañer O, Alfredo Martínez J, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Manuel Santos-Lozano J, Serra-Majem L, Bueno-Cavanillas A, Tur JA, Cinza Sanjurjo S, Pintó X, Juan Gaforio J, Matía-Martín P, Vidal J, Vázquez C, Daimiel L, Ros E, Sayon-Orea C, V Sorli J, Pérez-Vega KA, Garcia-Rios A, Ortiz-Díaz F, Gómez-Gracia E, Zulet MA, Chaplin A, Casas R, Salcedo-Bellido I, Tojal-Sierra L, Bernal-Lopez MR, Vazquez-Ruiz Z, Asensio EM, Goday A, Peña-Orihuela PJ, Signes-Pastor AJ, Garcia-Arellano A, Fitó M, Babio N, and Salas-Salvadó J
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Body Mass Index, Diabetes Mellitus, Type 2, Endocrine Disruptors, Diet statistics & numerical data, Aged, 80 and over, Prospective Studies, Environmental Pollutants blood, Alkanesulfonic Acids blood, Fluorocarbons blood, Homeostasis, Blood Glucose analysis
- Abstract
Background: Endocrine disruptors (EDs) have emerged as potential contributors to the development of type-2 diabetes. Perfluorooctane sulfonate (PFOS), is one of these EDs linked with chronic diseases and gathered attention due to its widespread in food., Objective: To assess at baseline and after 1-year of follow-up associations between estimated dietary intake (DI) of PFOS, and glucose homeostasis parameters and body-mass-index (BMI) in a senior population of 4600 non-diabetic participants from the PREDIMED-plus study., Methods: Multivariable linear regression models were conducted to assess associations between baseline PFOS-DI at lower bound (LB) and upper bound (UB) established by the EFSA, glucose homeostasis parameters and BMI., Results: Compared to those in the lowest tertile, participants in the highest tertile of baseline PFOS-DI in LB and UB showed higher levels of HbA1c [β-coefficient(CI)] [0.01 %(0.002 to 0.026), and [0.06 mg/dL(0.026 to 0.087), both p-trend ≤ 0.001], and fasting plasma glucose in the LB PFOS-DI [1.05 mg/dL(0.050 to 2.046),p-trend = 0.022]. Prospectively, a positive association between LB of PFOS-DI and BMI [0.06 kg/m
2 (0.014 to 0.106) per 1-SD increment of energy-adjusted PFOS-DI was shown. Participants in the top tertile showed an increase in HOMA-IR [0.06(0.016 to 0.097), p-trend = 0.005] compared to participants in the reference tertile after 1-year of follow-up., Discussion: This is the first study to explore the association between DI of PFOS and glucose homeostasis. In this study, a high baseline DI of PFOS was associated with a higher levels of fasting plasma glucose and HbA1c and with an increase in HOMA-IR and BMI after 1-year of follow-up., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
12. Association between Beverage Consumption and Environmental Sustainability in an Adult Population with Metabolic Syndrome.
- Author
-
García S, Monserrat-Mesquida M, Argelich E, Ugarriza L, Salas-Salvadó J, Bautista I, Vioque J, Zomeño MD, Corella D, Pintó X, Bueno-Cavanillas A, Daimiel L, Martínez JA, Nishi S, Herrera-Ramos E, González-Palacios S, Fitó M, Asensio EM, Fanlo-Maresma M, Cano-Ibáñez N, Cuadrado-Soto E, Abete I, Tur JA, and Bouzas C
- Subjects
- Adult, Humans, Middle Aged, Aged, Animals, Longitudinal Studies, Energy Intake, Beverages, Milk, Sugars, Metabolic Syndrome, Drinking Water
- Abstract
Beverages are an important part of the diet, but their environmental impact has been scarcely assessed. The aim of this study was to assess how changes in beverage consumption over a one-year period can impact the environmental sustainability of the diet. This is a one-year longitudinal study of 55-75-year-old participants with metabolic syndrome (n = 1122) within the frame of the PREDIMED-Plus study. Food and beverage intake were assessed using a validated food frequency questionnaire and a validated beverage-specific questionnaire. The Agribalyse
® 3.0.1 database was used to calculate environmental impact parameters such as greenhouse gas emission, energy, water, and land use. A sustainability beverage score was created by considering the evaluated environmental markers. A higher beverage sustainability score was obtained when decreasing the consumption of bottled water, natural and packed fruit juice, milk, and drinkable dairy, soups and broths, sorbets and jellies, soft drinks, tea without sugar, beer (with and without alcohol), and wine, as well as when increasing the consumption of tap water and coffee with milk and without sugar. Beverage consumption should be considered when assessing the environmental impact of a diet. Trial registration: ISRCTN, ISRCTN89898870. Registered 5 September 2013.- Published
- 2024
- Full Text
- View/download PDF
13. Coronavirus disease 2019 is associated with long-term depressive symptoms in Spanish older adults with overweight/obesity and metabolic syndrome.
- Author
-
Shyam S, Gómez-Martínez C, Paz-Graniel I, Gaforio JJ, Martínez-González MÁ, Corella D, Fitó M, Martínez JA, Alonso-Gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Santos-Lozano JM, Serra-Majem JL, Bueno-Cavanillas A, Tur JA, Martín Sánchez V, Pintó X, Ortiz Ramos M, Vidal J, Mar Alcarria M, Daimiel L, Ros E, Fernandez-Aranda F, Nishi SK, García Regata O, Toledo E, Sorli JV, Castañer O, Garcia-Rios A, Valls-Enguix R, Perez-Farinos N, Zulet MA, Rayó-Gago E, Casas R, Rivera-Izquierdo M, Tojal-Sierra L, Damas-Fuentes M, Buil-Cosiales P, Fernández-Carrion R, Goday A, Peña-Orihuela PJ, Compañ-Gabucio L, Diez-Espino J, Tello S, González-Pinto A, de la O V, Delgado-Rodríguez M, Babio N, and Salas-Salvadó J
- Subjects
- Humans, Female, Aged, Depression psychology, Overweight epidemiology, Obesity epidemiology, COVID-19 epidemiology, Metabolic Syndrome epidemiology
- Abstract
Background: The coronavirus disease 2019 (COVID-19) has serious physiological and psychological consequences. The long-term (>12 weeks post-infection) impact of COVID-19 on mental health, specifically in older adults, is unclear. We longitudinally assessed the association of COVID-19 with depression symptomatology in community-dwelling older adults with metabolic syndrome within the framework of the PREDIMED-Plus cohort., Methods: Participants ( n = 5486) aged 55-75 years were included in this longitudinal cohort. COVID-19 status (positive/negative) determined by tests (e.g. polymerase chain reaction severe acute respiratory syndrome coronavirus 2, IgG) was confirmed via event adjudication (410 cases). Pre- and post-COVID-19 depressive symptomatology was ascertained from annual assessments conducted using a validated 21-item Spanish Beck Depression Inventory-II (BDI-II). Multivariable linear and logistic regression models assessed the association between COVID-19 and depression symptomatology., Results: COVID-19 in older adults was associated with higher post-COVID-19 BDI-II scores measured at a median (interquartile range) of 29 (15-40) weeks post-infection [fully adjusted β = 0.65 points, 95% confidence interval (CI) 0.15-1.15; p = 0.011]. This association was particularly prominent in women ( β = 1.38 points, 95% CI 0.44-2.33, p = 0.004). COVID-19 was associated with 62% increased odds of elevated depression risk (BDI-II ≥ 14) post-COVID-19 when adjusted for confounders (odds ratio; 95% CI 1.13-2.30, p = 0.008)., Conclusions: COVID-19 was associated with long-term depression risk in older adults with overweight/obesity and metabolic syndrome, particularly in women. Thus, long-term evaluations of the impact of COVID-19 on mental health and preventive public health initiatives are warranted in older adults.
- Published
- 2024
- Full Text
- View/download PDF
14. The Impact of the Mediterranean Diet and Lifestyle Intervention on Lipoprotein Subclass Profiles among Metabolic Syndrome Patients: Findings of a Randomized Controlled Trial.
- Author
-
Candás-Estébanez B, Fernández-Cidón B, Corbella E, Tebé C, Fanlo-Maresma M, Esteve-Luque V, Salas-Salvadó J, Fitó M, Riera-Mestre A, Ros E, and Pintó X
- Subjects
- Humans, Cholesterol, LDL, Lipoproteins, Triglycerides, Cholesterol, Life Style, Metabolic Syndrome, Diet, Mediterranean
- Abstract
Metabolic syndrome (MetS) is associated with alterations of lipoprotein structure and function that can be characterized with advanced lipoprotein testing (ADLT). The effect of the Mediterranean diet (MedDiet) and weight loss on the lipoprotein subclass profile has been scarcely studied. Within the PREDIMED-Plus randomized controlled trial, a sub-study conducted at Bellvitge Hospital recruiting center evaluated the effects of a weight loss program based on an energy-reduced MedDiet (er-MedDiet) and physical activity (PA) promotion (intervention group) compared with energy-unrestricted MedDiet recommendations (control group) on ADLT-assessed lipoprotein subclasses. 202 patients with MetS ( n = 107, intervention; n = 95, control) were included. Lipid profiles were determined, and ADLT was performed at baseline, 6, and 12 months. Linear mixed models were used to assess the effects of intervention on lipoprotein profiles. Compared to the control diet, at 12 months, the er-MedDiet+PA resulted in a significant additional 4.2 kg of body weight loss, a decrease in body mass index by 1.4 kg/m
2 , reduction in waist circumference by 2.2 cm, decreased triglycerides, LDL-cholesterol and non-HDL-cholesterol, and increased HDL-cholesterol. In er-MedDiet+PA participants, ADLT revealed a decrease in small dense-LDL-cholesterol (sd-LDL-C), intermediate-density lipoproteins, VLDL-triglyceride, and HDL-Triglyceride, and an increase in large LDL and large VLDL particles. In conclusion, compared to an ad libitum MedDiet (control group), er-MedDiet+PA decreased plasma triglycerides and the triglyceride content in HDL and VLDL particles, decreased sd-LDL-C, and increased large LDL particles, indicating beneficial changes against cardiovascular disease.- Published
- 2024
- Full Text
- View/download PDF
15. Microbial Phenolic Metabolites Are Associated with Improved Cognitive Health.
- Author
-
Domínguez-López I, Galkina P, Parilli-Moser I, Arancibia-Riveros C, Martínez-González MÁ, Salas-Salvadó J, Corella D, Malcampo M, Martínez JA, Tojal-Sierra L, Wärnberg J, Vioque J, Romaguera D, López-Miranda J, Estruch R, Tinahones FJ, Santos-Lozano JM, Serra-Majem L, Bueno-Cavanillas A, Tur JA, Rubín-García M, Pintó X, Fernández-Aranda F, Delgado-Rodríguez M, Barabash-Bustelo A, Vidal J, Vázquez C, Daimiel L, Ros E, Toledo E, Atzeni A, Asensio EM, Vera N, Garcia-Rios A, Torres-Collado L, Pérez-Farinós N, Zulet M, Chaplin A, Casas R, Martín-Peláez S, Vaquero-Luna J, Gómez-Pérez AM, Vázquez-Ruiz Z, Shyam S, Ortega-Azorín C, Talens N, Peña-Orihuela PJ, Oncina-Canovas A, Diez-Espino J, Babio N, Fitó M, and Lamuela-Raventós RM
- Subjects
- Humans, Cross-Sectional Studies, Cognition, Glucuronides, Diet, Mediterranean psychology, 4-Butyrolactone analogs & derivatives, Lignans, Hydroxybenzoates
- Abstract
Scope: Diets rich in polyphenols has been associated with better cognitive performance. The aim of this study is to assess the relationship between microbial phenolic metabolites (MPM) in urine and cognition in the context of an older population at high cardiovascular risk., Methods and Results: A cross-sectional analysis is conducted in 400 individuals of the PREDIMED-Plus study. Liquid chromatography coupled to mass spectrometry is used to identify urinary MPM. Mediterranean diet (MedDiet) adherence is estimated with a 17-item questionnaire and cognitive function is evaluated with a battery of neuropsychological tests. Multivariable-adjusted linear regression models are fitted to assess the relationship of urinary MPM with the MedDiet and cognitive tests. Protocatechuic acid and enterolactone glucuronide are associated with higher adherence to the MedDiet. Regarding cognitive function, protocatechuic acid, vanillic acid glucuronide, 3-hydroxybenzoic acid, enterodiol glucuronide, and enterolactone glucuronide are directly associated with a global composite score of all the cognitive tests. Furthermore, protocatechuic acid and enterolactone glucuronide are associated with higher scores in the Mini-Mental State Examination, whereas enterodiol glucuronide is associated with improved Clock Drawing Test scores., Conclusions: These results suggest that the MedDiet is linked to MPM associated with better cognitive performance in an older population., (© 2023 The Authors. Molecular Nutrition & Food Research published by Wiley-VCH GmbH.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.